Shanghai Ark Biopharmaceutical Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-04-29
- Employees
- 51
- Market Cap
- -
Clinical Trials
17
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
A Clinical Study of AK0610
- Conditions
- Healthy Volunteer Study
- Interventions
- Drug: AK0610 Injection solutionDrug: Placebo
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT06996704
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital ）, Jinan, Shandong, China
A Study of AK0529 in Adults Patients Hospitalized With RSV Infection
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT06942299
- Locations
- 🇨🇳
The Second Perople's Hospital of Hefei, Hefei, Anhui, China
🇨🇳Huangshan City People's Hospital, Huangshan, Anhui, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
- Conditions
- Respiratory Synctial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06775405
- Locations
- 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, China
🇨🇳First Hospital of Jilin University, Changchun, China
🇨🇳Hunan Provincial People's Hospital, Changsha, China
Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06591845
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06359899
- Locations
- 🇨🇳
Beijing anding hospital capital medical university, Beijing, Beijing, China
🇨🇳Peking university sixth hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
ArkBio's AK3280 Shows Promising Results in Phase II IPF Trial with Significant Lung Function Improvement
ArkBio's novel anti-fibrotic drug AK3280 demonstrated significant improvement in lung function during Phase II trials for idiopathic pulmonary fibrosis, with the highest dose group showing a 209.4 mL increase in FVC.
ArkBio's AK0901 Completes Phase III Trial for ADHD in China, Showing Significant Efficacy
ArkBio has successfully completed Phase III clinical trials for AK0901, a novel methylphenidate-based drug for ADHD treatment, meeting all primary and secondary endpoints with statistical significance.